According to Howard K. Crowley, head of pharmacy strategic initiatives, Aetna Pharmacy Management, a Towers Watson/ National Business Group on Health survey found that 29% of employers rank the rising costs of specialty drugs as a top challenge to keeping health benefit coverage affordable.
According to Howard K. Crowley, head of pharmacy strategic initiatives, Aetna Pharmacy Management, a Towers Watson/ National Business Group on Health survey found that 29% of employers rank the rising costs of specialty drugs as a top challenge to keeping health benefit coverage affordable.
He says that while most prescriptions will be written for generic prescription drugs, most of the costs will be for specialty medication. In 2013 drug spending totaled $35 billion, but by 2021 is could be as high as $160 billion. He added that 77% of drug spend is associated with 6 therapeutic categories and 40% of drugs filed for FDA approval are specialty. Of course, specialty pharmacy costs are only part of the problem. Other challenges include the 90,000 projected shortfall of physicians by 2020, and the 46,000 projected shortfall of specialists by 2020.
There are a wide variety of specialty therapies for different conditions including multiple sclerosis (MS), hepatitis C, and in oncology. MS, for instance impacts an estimated 400,000 people in the United States, with about 10 drug treatment options. Hepatitis C has a prevalence of 3.2 million, more than 6 disease variations, and 7 drug treatment options.
Mr Crowley says that successful solutions must consider all the challenges, especially in areas such as treating MS, hepatitis C, and oncology. He argues that leaders in specialty pharmacy services require decisions supported by:
Pharmacy analytics should consider the drug choice, site of care, and support systems available. For example, a focus on oncology might include looking at the drug choice (ie, diagnosis validation, dose and frequency edits), the site of care (ie, oncology patient centered medical homes or tiered networks), and support (ie, case management or behavioral health).
Mr Crowley says that Aetna recognizes the changes required in traditional operating models that will allow the industry to meet the demands of employers. Collaboration can result in better outcomes, especially when medications are administered in a clinically appropriate setting at a rational price, and there are networks to support evidence-based medicine treatment pathways. As well, a wide array of benefit tools can ensure clinically appropriate therapy. Finally, patient, provider, and caregiver support systems should be designed to be efficient and deliver the best health outcomes.
“We need to take a broader look,” Mr Crowley says. “[Payers] working collaboratively with providers—that’s the future.”
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More